IXICO plc Share Price OTC Markets
Stocks
PHYOF
GB00BFXR4C20
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
12:36:20 14/02/2023 am IST
|
5-day change | 1st Jan Change | ||
| 0.7700 USD | -.--% |
|
+1,000.00% | +1,000.00% |
| 13/07 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 13/07 | Ixico notes ending of Huntington's disease programmes | AN |
| Market Cap | 1.64Cr 2.22Cr 1.91Cr 1.8Cr 3.07Cr 211.86Cr 3.13Cr 21Cr 8.24Cr 106.09Cr 8.32Cr 8.14Cr 352.56Cr | P/E 2026 * |
-5.36x | P/E 2027 * | -5.77x |
|---|---|---|---|---|---|
| Enterprise Value | 61.54L 83.37L 72.01L 67.66L 1.16Cr 80Cr 1.18Cr 7.93Cr 3.1Cr 40Cr 3.13Cr 3.06Cr 132.66Cr | EV / Sales 2026 * |
0.77x | EV / Sales 2027 * | 1.14x |
| Free-Float |
89.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: IXICO plc
| 1 week | +1,000.00% | ||
| Current month | +1,000.00% | ||
| 1 month | +1,000.00% | ||
| 3 months | +1,000.00% | ||
| 6 months | +1,000.00% | ||
| Current year | +1,000.00% |
| 3 years | 0.07 |  | 0.77 |
| 5 years | 0 | | 1.09 |
| 10 years | 0 | | 1.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 19/08/2024 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 21/08/2019 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 21/08/2019 |
Katherine Rogers
BRD | Director/Board Member | 60 | 21/01/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +1,000.00% | - | - | 2.22Cr | |
| -1.78% | -1.68% | +1.48% | +15.31% | 4.84TCr | |
| +0.85% | -0.70% | +460.88% | +563.55% | 4.37TCr | |
| -2.40% | -0.23% | +8.13% | +71.41% | 3.95TCr | |
| -2.01% | -0.85% | +23.85% | +8.73% | 3.9TCr | |
| -0.50% | +0.85% | +20.60% | +49.65% | 3.26TCr | |
| +0.38% | -3.23% | - | - | 1.63TCr | |
| -0.59% | -2.06% | +26.35% | +118.09% | 1.61TCr | |
| +0.49% | +0.92% | +4.11% | +23.67% | 1.42TCr | |
| -0.43% | +4.70% | +78.74% | +33.31% | 1.34TCr | |
| Average | -0.60% | +0.49% | +78.02% | +110.46% | 2.92TCr | |
| Weighted average by Cap. | -0.91% | +0.59% | +95.83% | +132.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 80L 1.08Cr 93.61L 87.97L 1.5Cr 103.64Cr 1.53Cr 10Cr 4.03Cr 52Cr 4.07Cr 3.98Cr 172.47Cr | 90L 1.22Cr 1.05Cr 98.96L 1.69Cr 116.59Cr 1.72Cr 12Cr 4.53Cr 58Cr 4.58Cr 4.48Cr 194.03Cr |
| Net income | -21.43L -29.03L -25.08L -23.56L -40.29L -28Cr -40.95L -2.76Cr -1.08Cr -14Cr -1.09Cr -1.07Cr -46Cr | -28.01L -37.95L -32.78L -30.8L -52.66L -36Cr -53.53L -3.61Cr -1.41Cr -18Cr -1.42Cr -1.39Cr -60Cr |
| Net Debt | -1.02Cr -1.38Cr -1.19Cr -1.12Cr -1.92Cr -132.14Cr -1.95Cr -13Cr -5.14Cr -66Cr -5.19Cr -5.08Cr -219.9Cr | -61L -82.64L -71.38L -67.07L -1.15Cr -79Cr -1.17Cr -7.86Cr -3.07Cr -40Cr -3.1Cr -3.04Cr -131.51Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IXI Stock
- PHYOF Stock
Select your edition
All financial news and data tailored to specific country editions
